190 related articles for article (PubMed ID: 24722351)
1. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.
McQuaid F; Snape MD; John TM; Kelly S; Robinson H; Houlden J; Voysey M; Toneatto D; Kitte C; Dull PM; Pollard AJ
Pediatr Infect Dis J; 2014 Jul; 33(7):760-6. PubMed ID: 24722351
[TBL] [Abstract][Full Text] [Related]
2. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.
Snape MD; Philip J; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Kittel C; Toneatto D; Dull PM; Pollard AJ
Pediatr Infect Dis J; 2013 Oct; 32(10):1116-21. PubMed ID: 23958808
[TBL] [Abstract][Full Text] [Related]
3. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.
Sadarangani M; Sell T; Iro MA; Snape MD; Voysey M; Finn A; Heath PT; Bona G; Esposito S; Diez-Domingo J; Prymula R; Odueyungbo A; Toneatto D; Pollard AJ;
CMAJ; 2017 Oct; 189(41):E1276-E1285. PubMed ID: 29038320
[TBL] [Abstract][Full Text] [Related]
4. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
Iro MA; Snape MD; Voysey M; Jawad S; Finn A; Heath PT; Bona G; Esposito S; Diez-Domingo J; Prymula R; Odueyungbo A; Toneatto D; Dull P; Pollard AJ;
Vaccine; 2017 Jan; 35(2):395-402. PubMed ID: 27914744
[TBL] [Abstract][Full Text] [Related]
5. Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age.
Snape MD; Voysey M; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Kieninger D; Prymula R; Dull PM; Kohl I; Barone M; Wang H; Toneatto D; Pollard AJ;
Pediatr Infect Dis J; 2016 Apr; 35(4):e113-23. PubMed ID: 26756390
[TBL] [Abstract][Full Text] [Related]
6. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
Snape MD; Saroey P; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Wang H; Toneatto D; Dull PM; Pollard AJ
CMAJ; 2013 Oct; 185(15):E715-24. PubMed ID: 24062178
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
Flacco ME; Manzoli L; Rosso A; Marzuillo C; Bergamini M; Stefanati A; Cultrera R; Villari P; Ricciardi W; Ioannidis JPA; Contopoulos-Ioannidis DG
Lancet Infect Dis; 2018 Apr; 18(4):461-472. PubMed ID: 29371070
[TBL] [Abstract][Full Text] [Related]
8. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
[TBL] [Abstract][Full Text] [Related]
9. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
Carter NJ
BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II).
Esposito S; Prymula R; Zuccotti GV; Xie F; Barone M; Dull PM; Toneatto D
Hum Vaccin Immunother; 2014; 10(7):2005-14. PubMed ID: 25424810
[TBL] [Abstract][Full Text] [Related]
11. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
[TBL] [Abstract][Full Text] [Related]
12. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
Gossger N; Snape MD; Yu LM; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Becker B; Kieninger D; Prymula R; Dull P; Ypma E; Toneatto D; Kimura A; Pollard AJ;
JAMA; 2012 Feb; 307(6):573-82. PubMed ID: 22318278
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.
Hosking J; Rasanathan K; Mow FC; Jackson C; Martin D; O'Hallahan J; Oster P; Ypma E; Reid S; Aaberge I; Crengle S; Stewart J; Lennon D
Clin Vaccine Immunol; 2007 Nov; 14(11):1393-9. PubMed ID: 17898183
[TBL] [Abstract][Full Text] [Related]
17. Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.
McQuaid F; Snape MD; John TM; Kelly S; Robinson H; Yu LM; Toneatto D; D'Agostino D; Dull PM; Pollard AJ
CMAJ; 2015 Apr; 187(7):E215-E223. PubMed ID: 25802309
[TBL] [Abstract][Full Text] [Related]
18. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
[TBL] [Abstract][Full Text] [Related]
19. Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: Lessons of the Normandy campaign.
Sevestre J; Hong E; Delbos V; Terrade A; Mallet E; Deghmane AE; Lemée L; Taha MK; Caron F
Vaccine; 2017 Jul; 35(32):4029-4033. PubMed ID: 28624305
[TBL] [Abstract][Full Text] [Related]
20. Will booster doses be required for serogroup B meningococcal vaccine?
McQuaid F; Snape MD
Expert Rev Vaccines; 2014 Mar; 13(3):313-5. PubMed ID: 24451002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
